CADL Forex Haberleri
Candel Therapeutics Says FDA Grants Orphan Drug Designation For CAN-3110 To Treat High-grade Glioma
Biopharmaceutical company Candel Therapeutics, Inc. (CADL) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-3110 for the treatment of recurrent high-grade glioma (rHGG). Glioblastoma (GBM) is the most common and aggressive form of high-grade glioma.
RTTNews
|
905 gün önce
